PLX 5622

Drug Profile

PLX 5622

Alternative Names: PLX5622

Latest Information Update: 19 May 2015

Price : $50

At a glance

  • Originator Plexxikon
  • Class Antirheumatics; Small molecules
  • Mechanism of Action Type 1 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 19 May 2015 Discontinued - Phase-I for Rheumatoid arthritis in USA (PO)
  • 30 Nov 2011 Plexxikon completes a phase I trial in Rheumatoid arthritis in US (NCT01329991)
  • 04 Apr 2011 Plexxikon has been acquired by Daiichi Sankyo Company
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top